A new book examines the potential of magic mushrooms to address obsessive-compulsive disorder, often called the doubting disorder.
The excerpt describes a scene in New York City where Adam Strauss debates between two MP3 players while holding his headphones cord. It draws on the idea of OCD as uncertainty and questions if psilocybin could help reduce that doubt.
A placebo-controlled trial has shown that a single dose of psilocybin, the active ingredient in magic mushrooms, leads to rapid and lasting reductions in obsessive-compulsive disorder symptoms among treatment-resistant patients. The effects persisted for at least 12 weeks in participants who had not responded to conventional therapies. Researchers highlight the potential of this psychedelic for mental health treatment, though larger studies are needed.
Rapporteret af AI
President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate access to psychedelic drugs like psilocybin and ibogaine for treating mental health conditions, including depression, anxiety, and PTSD. The order allocates $50 million in funding and instructs the FDA to prioritize reviews. Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell, and podcast host Joe Rogan.
Science journalist Michaeleen Doucleff appeared on CBS Saturday Morning to discuss her new book, Dopamine Kids. She offered advice for parents aiming to reduce their children's screen time and junk food consumption. The discussion highlights practical strategies rooted in scientific insights.
Rapporteret af AI
A randomized clinical trial found that 24 minutes of specially designed music paired with auditory beat stimulation significantly lowers anxiety symptoms. Researchers at Toronto Metropolitan University tested various listening durations on 144 adults with moderate anxiety. The 24-minute session provided the strongest benefits.